Format

Send to

Choose Destination
See comment in PubMed Commons below
Can J Physiol Pharmacol. 2008 Aug;86(8):473-84. doi: 10.1139/Y08-058.

The endothelin axis in cancer: the promise and the challenges of molecularly targeted therapy.

Author information

1
Molecular Pathology and Ultrastructure Laboratory, Regina Elena Cancer Institute, Via delle Messi d'Oro 156, Rome, Italy. bagnato@ifo.it

Abstract

The endothelin (ET) axis, which includes ET-1, ET-2, ET-3, and 2 G protein-coupled receptor subtypes, ET AR and ET BR, promotes growth and progression of a variety of tumors, such as prostatic, ovarian, renal, pulmonary, colorectal, cervical, breast, lung, bladder, endometrial carcinoma, Kaposi's sarcoma, brain tumors, and melanoma. Acting on selective receptors, ET-1 regulates mitogenesis, cell survival, angiogenesis, bone remodeling, stimulation of nociceptors, tumor-infiltrating immune cells, epithelial-to-mesenchymal transition, invasion, and metastatic dissemination. At the molecular level, endothelin receptor antagonists, besides providing ideal tools for dissecting the ET axis, have demonstrated their potential in developing novel therapeutic strategies. Emerging experimental and clinical data demonstrate that interfering with endothelin receptors provides an opportunity for the development of rational combinatorial approaches using endothelin receptor antagonists in combination with chemotherapy or molecularly targeted therapy.

PMID:
18758494
DOI:
10.1139/Y08-058
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center